NEW YORK (GBI Research), 12 April 2012 - The development of new diabetes medications are now more-commonly the result of deals between companies, a new report by pharmaceutical intelligence expert GBI Research has found. The new report* found that while major companies account for significant shares of the market, smaller companies are more able to compete using new strategies involving mergers, acquisitions, licensing deals and co-operation within the market, which is expected to boost product development until at least 2017.
Over 60 million people around the world suffer from diabetes, with the diabetic population currently rising further in key markets such as the US, the UK and Germany, increasing the profitability of popular diabetes therapeutics. While the diabetes market is presently dominated by insulins, demand remains for products that are easier for patients to administer, and this growth potential is driving deals activity in the industry.
Product failures such as GSK’s Avandia (rosiglitazone) and Takeda’s Actos, which were found to increase the probability of heart-related complications, have further increased the need for promising pipeline molecules to reduce dependency on drugs such as insulin analogues and biguanides. This has led to increased competition in the market and paved the way for agreements between companies that would have previously been rivals.
GBI Research has found that licensing agreements and co-developments accounted for the majority of the total 295 deals that took place during 2004-2011. Major acquisition activity also took place in 2010, including the acquisition by Astellas Pharma of OSI Pharmaceuticals in June 2010, and Sanofi’s acquisition of Ascendis Pharma’s worldwide rights to a gradual release technology for diabetes drugs.
GBI Research anticipates that the diabetes therapeutics mergers and acquisitions landscape will continue to be active in the future, as several pharmaceutical players are seeking strategic partnerships with companies that boast promising marketed or pipeline drugs. Future licensing activities involving approved products such as Januvia and Galvus, and Phase III products such as Oral-lyn, will also significantly impact the market.
*Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists
The report provides insights into diabetes therapeutics sales and price forecasts until 2017. The report also examines the global diabetes therapies’ treatment usage patterns. The report covers the key geographies of the US, the top five countries in the European region, and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of the two diabetes therapeutic indications, which are Type 1 and Type 2 diabetes. In addition, it includes market forecasts and treatment usage patterns for these two therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com
